Do Any Subgroups of Resected Biliary Tract Cancers Patients That Benefit the Most from Adjuvant Chemoradiation Therapy?
- 11 September 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 27 (S3), 934-936
- https://doi.org/10.1245/s10434-020-09128-8
Abstract
No abstract availableFunding Information
- Science & Technology Support Project of Sichuan Province (2018JY0019)
- Sichuan University Postdoctoral Interdisciplinary Innovation Start-up Fund (0040204153244)
- Post-Doctor Research Project, West China Hospital, Sichuan University (2019HXBH025)
- Fundamental Research Funds for the Central Universities (2019SCUH0021)
This publication has 6 references indexed in Scilit:
- Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After ChemoradiationAnnals of Surgical Oncology, 2020
- Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancersHPB, 2020
- Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resectionThe American Journal of Surgery, 2019
- Adjuvant Therapy for Gallbladder Cancer: an Analysis of the National Cancer Data BaseJournal of Gastrointestinal Surgery, 2015
- SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaJournal of Clinical Oncology, 2015
- Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2012